BLUE EARTH THERAPEUTICS' BOARD MEMBERS

David Gauden is the Chief Executive Officer (CEO) of Blue Earth Therapeutics Ltd.  A co-founder of sister company, Blue Earth Diagnostics, established in 2014, he was instrumental in rapidly advancing its portfolio and building the company from a start-up into a successful global organization.  Previously David was Product Leader for oncology molecular imaging at GE Healthcare, with business responsibility for the portfolio mix, licensing, product development and strategic marketing activities for a range of developmental PET drugs. Now with more than 25 years’ experience in the radiopharmaceuticals industry, David has deep expertise across the business spectrum. David has an undergraduate degree from the University of Warwick and a doctorate in Biochemistry from the University of Oxford.

Fabio started his career at Bruker as an Application Specialist and Project Leader, moving to Bracco Imaging S.p.A. in 2008. Starting as Preclinical Imaging Department Manager in the R&D Centre based in Ivrea, he subsequently held the position of Director of the same Centre and today the role of Director of R&D of the Global Business Unit Imaging of Bracco.

Fabio is also Managing Director of SurgVision GmBH, member of the Board of Directors of Blue Earth Diagnostics as well as of the Gruppo Tecnico Ricerca e Sviluppo of Confindustria and of the Gruppo Tecnico Università e Ricerca of Assolombarda.

His scientific CV includes approximately 45 peer-reviewed manuscripts and 10 patents.

Fabio holds a Ph.D. in Physics from the University of Pavia.

Andrea is Chief Executive Officer at Equita, the leading investment bank in Italy, is also a member of the ASSOSIM executive committee, the Italian Association of Financial Markets Intermediaries, member of the stakeholder group of CONSOB, Italy’s financial markets supervisor, and of the Advisory Board to Borsa Italiana, the Italian Stock Exchange. Andrea is also a member of the Board of Directors of Blue Earth Diagnostics.

Andrea graduated Magna cum laude in Business administration from the Bocconi University in Milan, with part of his studies at New York University. He began his career in capital markets and investment banking in London in 1990, at Goldman Sachs International, initially in the Corporate Finance and Debt Capital Markets departments. From 1995 to 2006, Andrea divided his time between the Milan and London offices of Barclays de Zoete Wedd (later acquired by Credit Suisse) and Credit Suisse, first as a member of the M&A team, then as Head of Equity Capital Markets for the Italian and Southern European markets then later as a senior coverage officer and legal representative of CSFB’s Italian branch in Milan. 

Cyrille joined Bracco S.p.A. in 2019 as Chief Corporate Development Officer and Head of Strategic Initiatives.

Cyrille started his career in investment banking, at Goldman Sachs in London then joined General Electric, where he had a 15-year tenure holding various position in Global Business Development. He left to join the executive committee of Smith & Nephew plc, as Chief Corporate Development Officer and Head of Global Business Services.

Cyrille has a strong track-record in strategy, M&A, building global support functions, running integration, cost reduction programs, and advising boards. He sits on the board of several medical technology companies, including Virbac, Polarean and Reapplix.

Cyrille holds a Master’s degree in Finance from HEC Paris.

David is a Partner at Soleus Capital where he focuses on private and public therapeutic and next-generation diagnostic companies. In addition to Blue Earth, David currently serves on the boards of a number of companies including Inhibikase, Twinstrand Biosciences, and Parse Biosciences. Prior to joining Soleus in 2018, David completed his PhD at MIT in Immunology and Oncology after finishing his undergraduate studies at Princeton University.

Michael is a Partner at Sands Capital, a leading growth-oriented investment firm. Since joining Sands Capital in 2011, he has invested in life sciences businesses across the private and public markets, with a primary focus on therapeutics. In addition to Blue Earth, he also serves on the boards of Prilenia Therapeutics, Inspirna, and as a board observer at Avenzo Therapeutics.  Michael earned a BS in commerce from the University of Virginia in 2011 and has been a CFA charterholder since 2015.